Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Gan To Kagaku Ryoho ; 50(6): 707-711, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37317605

RESUMEN

This study aimed to identify the risk factors of febrile neutropenia(FN)onset associated with melphalan(L-PAM)therapy. Thirty-nine patients(21 men, 18 women)were administered L-PAM intravenously for multiple myeloma(MM)from April 2011 to February 2022 at the Department of Hematology of Gifu Municipal Hospital. Patients were classified into those with and without FN(Grade 3 or higher), complete blood count and liver function tests were performed immediately before starting therapy. Univariate analysis with Fisher's exact probability test was performed. Factors with p<0.2 were considered as independent variables for multivariate analysis in the multiple logistic regression analysis. A multivariate analysis with 2 independent variables, lactate dehydrogenase(LD)level>222 U/L(upper limit of the facility reference value)and white <3.3×103/µL(lower limit of the facility reference value)from the univariate analysis, and FN onset(Grade 3 or higher)as the dependent variable showed that LD level>222 U/L(odds ratio: 6.33, 95% confidence interval: 1.12-35.8, p=0.037)was a significant factor. In conclusion, patients with LD levels >222 U/L immediately before starting therapy require adequate monitoring for FN onset following L-PAM administration.


Asunto(s)
Neutropenia Febril , Mieloma Múltiple , Masculino , Humanos , Femenino , Melfalán/efectos adversos , Mieloma Múltiple/tratamiento farmacológico , Hospitales Municipales , Factores de Riesgo , Neutropenia Febril/inducido químicamente
2.
Gan To Kagaku Ryoho ; 46(10): 1547-1551, 2019 Oct.
Artículo en Japonés | MEDLINE | ID: mdl-31631137

RESUMEN

Using electronic medical charts at the department of pharmacy of Gifu Municipal Hospital, we constructed a new support system for the prescription inspection of anticancer drug injection preparation via quality control. The system comprises: (1)a "regimen inspection sheet" that can be easily used to check the regimen and clinical laboratory data of patients before the administration of anticancer drugs and(2)an "instruction sheet confirming implementation" that can conveniently confirm the latest clinical laboratory data used to decide the administration of anticancer drugs. Using this system, the safety of anticancer drug administration and work efficiency may be improved.


Asunto(s)
Antineoplásicos/administración & dosificación , Servicio de Farmacia en Hospital , Prescripciones de Medicamentos , Humanos , Control de Calidad
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda